Pharmaceuticals, Biotechnology and Life Sciences
Adaptive Biotechnologies today announced Kevin Conroy, chairman and CEO
of Exact Sciences Corporation, and Michelle Griffin, director at Acer
Therapeutics, Inc. and HTG Molecular Diagnostics, Inc., have been
elected to the board of directors. Board member Arnold J. Levine, PhD,
has transitioned to Adaptive’s scientific advisory board.
Schrödinger
today announced that Ramy Farid, Ph.D., chief executive officer, will
present at the Jefferies 2019 Global Healthcare Conference on Thursday,
June 6, 2019 at 11:00 a.m. ET in New York, NY.
EUSA Pharma’s studies of Qarziba in treatment of high-risk neuroblastoma support the use of dinutuximab beta as standard-of-care immunotherapy for high-risk neuroblastoma patients.
Ansun Biopharma has welcomed the first patient to its Phase 3 clinical trial to test DAS181 a recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells lining the human respiratory track.
The LYRICA Pediatric Epilepsy Program is composed of six studies in
patients with epilepsy evaluating LYRICA as adjunctive therapy, five of
which have been completed.
Medicure Inc reported net loss for the quarter ended March 31, 2019 at $2.8 million compared to net income of $1.4 million for the quarter ended March 31, 2018.
Jakafi is the first and only FDA-approved treatment for patients with
steroid-refractory acute graft-versus-host disease (GVHD)
Eli Lilly’s Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly’s rapid-acting insulin and need a lower-cost option, the company said Wednesday.
Mayne Pharma Group Limited got approval from the USFDA for Sorilux foam, 0.005% in adolescents, for treating plaque psoriasis of the scalp and body in patients 12 years and older.